Researchers reclassified 86 percent of variants initially determined to be VUS, potentially changing surveillance or treatment approaches for patients.
The test uses primers and probes from Thermo Fisher Scientific's authorized TaqPath COVID-19 Combo Kit with a modified results interpretation algorithm.
The MAGENTA and ProGen trials showed that video-based and online education can increase the number of patients getting tested compared to traditional approaches.
The deal includes integrating an online ordering process for Ambry's genetic tests into Volpara's Aspen Breast software for medical practice management.
The company believes results from a new study help demonstrate the clinical value of its targeted RNA-seq method, an add-on to its DNA hereditary cancer tests.
Currently available under a soft launch, the tool can provide information about the prevalence of cancer risk mutations based on patients' demographics.
